![Daré Bioscience, Inc. on X: "Next Thursday, we will be hosting a conference call and live webcast to discuss our full-year 2021 financial results and provide a company update on March 31st Daré Bioscience, Inc. on X: "Next Thursday, we will be hosting a conference call and live webcast to discuss our full-year 2021 financial results and provide a company update on March 31st](https://pbs.twimg.com/media/FOomO_mVUAowXw4.jpg)
Daré Bioscience, Inc. on X: "Next Thursday, we will be hosting a conference call and live webcast to discuss our full-year 2021 financial results and provide a company update on March 31st
![Daré Bioscience, Inc. on X: "We announced positive topline results from our Phase 1 study of DARE-PDM1, which has potential to be a first-in-category product delivering diclofenac, a nonsteroidal anti-inflammatory drug, vaginally Daré Bioscience, Inc. on X: "We announced positive topline results from our Phase 1 study of DARE-PDM1, which has potential to be a first-in-category product delivering diclofenac, a nonsteroidal anti-inflammatory drug, vaginally](https://pbs.twimg.com/media/GBzFEbNWoAEsZOK.jpg)
Daré Bioscience, Inc. on X: "We announced positive topline results from our Phase 1 study of DARE-PDM1, which has potential to be a first-in-category product delivering diclofenac, a nonsteroidal anti-inflammatory drug, vaginally
![Daré Bioscience, Inc. to Post FY2025 Earnings of $0.10 Per Share, HC Wainwright Forecasts (NASDAQ:DARE) - Defense World Daré Bioscience, Inc. to Post FY2025 Earnings of $0.10 Per Share, HC Wainwright Forecasts (NASDAQ:DARE) - Defense World](https://www.marketbeat.com/logos/dar%C3%A9-bioscience-inc-logo-1200x675.png?v=20221223184841)